Tag: clinical trials for neuroendocrine tumors
10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community
As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…
READ MORE
Breaking News: US FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors
December 16, 2014: The US Food and Drug Administration (FDA) today approved “lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic…
READ MORE
Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome
Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…
READ MORE
Clinical Trials Resources for Carcinoid Cancer & Neuroendocrine Tumor Patients
Carcinoid and neuroendocrine tumor patients can have the latest information about clinical trials delivered directly to their computers – by RSS feed or e-mail. Go to https://clinicaltrials.gov/, in the search field enter the type of trial you are…
READ MORE
